VYNE VYNE Therapeutics, Inc. Quick Ratio

The linear price action on the GURU.Markets platform chart for VYNE Therapeutics (VYNE), where the coefficient is 21.45, demonstrates the business's resilience to economic cycles due to stable demand for dermatology. VYNE Therapeutics (VYNE) relies on the sale of certified products, although aggressive marketing reduces revenue transparency. Meanwhile, a high burn rate and uncertainty regarding clinical trial outcomes create significant financial risks.

VYNE Therapeutics' high reliance on external CROs and CMOs necessitates a constant operational reserve to fund contracts. This metric is calculated by dividing the sum of cash and accounts receivable by current liabilities, completely excluding illiquid inventories. Such an approach allows for a real-time assessment of the business's solvency without relying on the liquidation of warehouse stocks. By analyzing this strict liability coverage ratio, an investor determines the company's ability to service debts under tight timing constraints.